| Primary |
| Prostate Cancer |
62.4% |
| Hypertension |
8.3% |
| Prostate Cancer Metastatic |
8.3% |
| Asthma |
4.1% |
| Cardiac Disorder |
1.8% |
| Metastases To Bone |
1.8% |
| Benign Prostatic Hyperplasia |
1.4% |
| Breast Cancer Metastatic |
1.4% |
| Neoplasm Prostate |
1.4% |
| Thrombosis Prophylaxis |
1.4% |
| Aortic Valve Incompetence |
0.9% |
| Atrial Fibrillation |
0.9% |
| Gastric Ulcer |
0.9% |
| Hypertonic Bladder |
0.9% |
| Hypocalcaemia |
0.9% |
| Prophylaxis |
0.9% |
| Prostate Cancer Recurrent |
0.9% |
| Analgesia |
0.5% |
| Breast Cancer |
0.5% |
| Bronchiectasis |
0.5% |
|
| Interstitial Lung Disease |
14.3% |
| Cerebral Infarction |
9.9% |
| Pulmonary Embolism |
7.7% |
| Decreased Appetite |
6.6% |
| Jaundice |
5.5% |
| Malaise |
5.5% |
| Pharyngeal Oedema |
5.5% |
| Pleural Effusion |
5.5% |
| Angioedema |
4.4% |
| Cardiac Failure |
4.4% |
| Death |
4.4% |
| Renal Failure Acute |
4.4% |
| Myocardial Infarction |
3.3% |
| Neoplasm Malignant |
3.3% |
| Vomiting |
3.3% |
| White Blood Cell Count Increased |
3.3% |
| Alanine Aminotransferase Increased |
2.2% |
| Cardiac Failure Congestive |
2.2% |
| Coagulation Time Prolonged |
2.2% |
| Drug Interaction |
2.2% |
|
| Secondary |
| Prostate Cancer |
37.1% |
| Breast Cancer Metastatic |
9.2% |
| Breast Cancer |
8.0% |
| Metastases To Bone |
5.2% |
| Hypertension |
4.3% |
| Prostate Cancer Metastatic |
4.3% |
| Prostate Cancer Stage Iv |
4.0% |
| Product Used For Unknown Indication |
3.7% |
| Diabetes Mellitus |
3.4% |
| Drug Use For Unknown Indication |
3.1% |
| Thrombosis Prophylaxis |
3.1% |
| Benign Prostatic Hyperplasia |
2.8% |
| Hypertonic Bladder |
1.8% |
| Metastases To Pleura |
1.8% |
| Anticoagulant Therapy |
1.5% |
| Hypocalcaemia |
1.5% |
| Platelet Count Decreased |
1.5% |
| White Blood Cell Count Decreased |
1.5% |
| Hormone Therapy |
1.2% |
| Prophylaxis |
0.9% |
|
| Renal Failure Acute |
17.3% |
| Decreased Appetite |
6.7% |
| Malaise |
6.7% |
| Tongue Neoplasm Malignant Stage Unspecified |
6.7% |
| Cardiac Failure |
5.3% |
| Cardiac Failure Congestive |
5.3% |
| Coagulation Time Prolonged |
5.3% |
| Desmoid Tumour |
5.3% |
| Venous Thrombosis Limb |
5.3% |
| Vomiting |
5.3% |
| Face Oedema |
4.0% |
| Interstitial Lung Disease |
4.0% |
| White Blood Cell Count Increased |
4.0% |
| Dyspnoea |
2.7% |
| Gastrooesophageal Reflux Disease |
2.7% |
| Hypoproteinaemia |
2.7% |
| Intra-abdominal Haemorrhage |
2.7% |
| Leukaemia |
2.7% |
| Malignant Neoplasm Progression |
2.7% |
| Nausea |
2.7% |
|
| Concomitant |
| Prostate Cancer |
37.2% |
| Metastases To Bone |
13.3% |
| Prostate Cancer Stage Iv |
8.5% |
| Product Used For Unknown Indication |
8.1% |
| Premedication |
4.6% |
| Benign Prostatic Hyperplasia |
3.1% |
| Pain |
3.1% |
| Prostate Cancer Recurrent |
2.9% |
| Breast Cancer |
2.4% |
| Breast Cancer Metastatic |
2.2% |
| Prostate Cancer Metastatic |
2.2% |
| Lobar Pneumonia |
1.7% |
| Adjuvant Therapy |
1.5% |
| Dysuria |
1.5% |
| Gastritis |
1.5% |
| Hypertension |
1.5% |
| Cancer Pain |
1.3% |
| Drug Use For Unknown Indication |
1.3% |
| Cataract |
1.1% |
| Diabetes Mellitus |
1.1% |
|
| Prostate Cancer |
13.3% |
| Interstitial Lung Disease |
12.0% |
| Osteonecrosis |
9.6% |
| Renal Impairment |
9.6% |
| Tongue Neoplasm Malignant Stage Unspecified |
4.8% |
| Toothache |
4.8% |
| Visual Acuity Reduced |
4.8% |
| Asthenia |
3.6% |
| Hepatic Failure |
3.6% |
| Neoplasm Malignant |
3.6% |
| Osteomyelitis |
3.6% |
| Petechiae |
3.6% |
| Prostate Cancer Recurrent |
3.6% |
| Respiratory Failure |
3.6% |
| Tooth Extraction |
3.6% |
| Arrhythmia |
2.4% |
| Decreased Appetite |
2.4% |
| Disease Progression |
2.4% |
| Disseminated Intravascular Coagulation |
2.4% |
| Malaise |
2.4% |
|
| Interacting |
| Hormone Therapy |
77.8% |
| Hypertension |
11.1% |
| Prostate Cancer |
11.1% |
|
| Drug Interaction |
50.0% |
| Tongue Oedema |
50.0% |
|
